论文部分内容阅读
以均含有利福平及氨苯砜的三组MDT方案治疗了278例PB病人。方案Ⅰ是由WHO研究小组建议的。方案Ⅱ在方案Ⅰ的基础上再用氨苯砜治疗6个月。方案Ⅲ在治疗第一周每日服用利福平,其它与方案Ⅱ相同。治疗一年后,方案Ⅱ和方案Ⅲ组病人的非活动性大大超过方案Ⅰ组病人。(为94％,97％对76％)。在随访三年半中,方案Ⅰ、方案Ⅱ、方案Ⅲ组病人的复发率分别为13％,1％,2％。因为三个方案组的病人具有可比性,所以我们推断,方案Ⅱ及Ⅲ组病人之所以有高的非活动性,低复发率(1％～2％),以及无早期和晚期麻风反应是由于足够的治疗。
A total of 278 patients with PB were treated with three MDT regimens containing both rifampin and dapsone. Protocol I was proposed by the WHO research team. Scenario Ⅱ was further treated with dapsone for 6 months on the basis of protocol Ⅰ. Option Ⅲ in the first week of treatment taking rifampicin daily, the other with the same program Ⅱ. After one year of treatment, the inactivity of the patients in the scheme II and the scheme III group greatly exceeded that of the scheme I group. (94%, 97% vs 76%). During the three-and-a-half year follow-up, the recurrence rates were 13%, 1%, and 2% for patients in protocol I, II, and III respectively. Because of the comparability of patients in the three program groups, we concluded that patients in groups II and III had high rates of inactivity, low recurrence (1% -2%), and absence of early and late leprosy due to Sufficient treatment.